September 5, 2018
General Session – Dr. Kathleen Blake, MD, MPH, will describe the value of NESTcc for stakeholder groups, with special emphasis on clinicians. Interim Governing Committee Chair Michelle McMurry-Heath, MD, PhD, will share her vision for the role of NESTcc in opening the front door to targeted test-case initiatives while Jeffrey Shuren, MD, JD will discuss the role of NESTcc in addressing FDA pre- and post-market priorities.
Breakout Session – Doctors Lesley Curtis, PhD, MS, and Joe Drozda, MD, FACC, will share insights as test-case project leaders, including lessons learned, the benefits of working with NESTcc, and innovative solutions. Dr. Curtis will also provide insights as the Chair of the NESTcc Data Quality Committee. Dr. Paul Coplan, ScD, MBA, FISPE, will provide an industry perspective on the value of the NESTcc test-case initiative.
General Session Moderator: Rachael Fleurence, PhD | Executive Director | National Evaluation System for health Technology Coordinating Center
Breakout Session Moderator: Owen Faris, PhD | Clinical Trials Director | Office of Device Evaluation, Center for Devices and Radiological Health, U.S. Food and Drug Administration
Center for Total Health
700 Second St. NE
Washington, DC 20002